a Department of Radiation Oncology , University Hospital of Besançon , Besançon , France.
b Department of Biostatistics , Georges François Leclerc Center, University of Burgundy , Dijon , France.
Acta Oncol. 2018 Apr;57(4):491-497. doi: 10.1080/0284186X.2017.1369565. Epub 2017 Aug 30.
Radical cystectomy (RC) and radiochemotherapy (RCT) are curative options for muscle-invasive bladder cancer (MIBC). Optimal treatment strategy remains unclear in elderly patients.
Patients aged 80 years old and above with T2-T4aN0-2M0-Mx MIBC were identified in the Retrospective International Study of Cancers of the Urothelial Tract (RISC) database. Patients treated with RC were compared with those treated with RCT. The impact of surgery on overall survival (OS) was assessed using a Cox proportional hazard model. Progression included locoregional and metastatic relapse and was considered a time-dependent variable.
Between 1988 and 2015, 92 patients underwent RC and 72 patients had RCT. Median age was 82.5 years (range 80-100) and median follow-up was 2.90 years (range 0.04-11.10). Median OS was 1.99 years (95%CI 1.17-2.76) after RC and 1.97 years (95%CI 1.35-2.64) after RCT (p = .73). Median progression-free survival (PFS) after RC and RCT were 1.25 years (95%CI 0.80-1.75) and 1.52 years (95%CI 1.01-2.04), respectively (p = .54). In multivariate analyses, only disease progression was significantly associated with worse OS (HR = 10.27 (95%CI 6.63-15.91), p < .0001). Treatment modality was not a prognostic factor.
RCT offers survival rates comparable to those observed with RC for patients aged ≥80 years.
根治性膀胱切除术(RC)和放化疗(RCT)是肌层浸润性膀胱癌(MIBC)的治愈选择。在老年患者中,最佳治疗策略仍不明确。
在回顾性国际尿路上皮癌研究(RISC)数据库中,确定了年龄在 80 岁及以上、患有 T2-T4aN0-2M0-MxMIBC 的患者。将接受 RC 治疗的患者与接受 RCT 治疗的患者进行比较。使用 Cox 比例风险模型评估手术对总生存期(OS)的影响。进展包括局部和远处复发,被视为一个时间相关的变量。
在 1988 年至 2015 年间,92 例患者接受了 RC,72 例患者接受了 RCT。中位年龄为 82.5 岁(范围 80-100),中位随访时间为 2.90 年(范围 0.04-11.10)。RC 治疗后 OS 的中位时间为 1.99 年(95%CI 1.17-2.76),RCT 治疗后为 1.97 年(95%CI 1.35-2.64)(p=0.73)。RC 和 RCT 治疗后 PFS 的中位时间分别为 1.25 年(95%CI 0.80-1.75)和 1.52 年(95%CI 1.01-2.04)(p=0.54)。多变量分析显示,只有疾病进展与 OS 较差显著相关(HR=10.27(95%CI 6.63-15.91),p<0.0001)。治疗方式不是预后因素。
对于年龄≥80 岁的患者,RCT 提供的生存率与 RC 观察到的生存率相当。